204 related articles for article (PubMed ID: 19689476)
1. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
Niu Y; Terasaki Y; Komatsu N; Noguchi M; Shichijo S; Itoh K
Cancer Sci; 2009 Nov; 100(11):2167-74. PubMed ID: 19689476
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
3. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
4. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Sasada T; Azuma K; Ishihara Y; Komohara Y; Noguchi M; Shichijo S; Itoh K; Harada M
J Immunother; 2007 Apr; 30(3):274-81. PubMed ID: 17414318
[TBL] [Abstract][Full Text] [Related]
5. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
[TBL] [Abstract][Full Text] [Related]
6. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
7. [Generation of HER2 specific, HLA-A24 restricted CTLs derived from gastric cancer patients].
Mimura K; Kono K; Sugai H; Miyagawa N; Omata H; Fujii H; Matsumoto Y
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1802-4. PubMed ID: 14619524
[TBL] [Abstract][Full Text] [Related]
8. [Human tumor-rejection antigens and peptides from genes to clinical research].
Itoh K; Yamana H; Shichijo S; Yamada A
Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
[TBL] [Abstract][Full Text] [Related]
9. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
10. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
11. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
13. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
15. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
16. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
[TBL] [Abstract][Full Text] [Related]
18. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M
Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]